All press releases Newsroom
An independent evaluation confirms the clinical and organizational benefits of the Medherize platform in breast oncology
An independent evaluation conducted by the Breast Disease Centre of CHU de Québec – Université Laval among 243 breast cancer patients on targeted oral therapies demonstrates measurable benefits: a 97% adoption rate, 93% treatment adherence, treatment interruptions cut to 17% against roughly 50% expected in the literature, and a 52% reduction in the pharmacist full-time equivalent required.
The PDF is the official version of the release.